This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

STEPHANE BLANCHE, MD; ANNE-MARIE DULIEGE, MD; CHRISTINE Rouzioux, MD; FRANÇOISE LE DEIST, MD; KEN FUKUNAGA, MD; MAURIZIO CANIGLIA, MD; CHRISTINE JACOMET, MD; CLAUDE GRISCELLI, MD
Pediatric Immunology Division, INSERM U 132, and Virology Unit Hopital Necker 149 rue de Sèvres 75015 Paris, France MARC TARDIEU, MD Pediatric Neurology Division, INSERM U 56

ANTOINE MESSIAH, PHD
Epidemiology Division, INSERM U 292 Bicêtre Hospital Paris, France

Am J Dis Child. 1991;145(12):1349.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—We fully agree with the comments by Drs Katz and McNamara regarding the various types of disease progressions in children infected with (HIV). Indeed, some patients with a "borderline" or an unusual progression might not perfectly fit into our description of a "bimodal population" of children according to the progression of the disease.¹ We followed up a child, perinatally infected with HIV, who, at age 4 months, developed Pneumocystis carinii pneumonia. Three years later she was well, with no neurologic impairment or secondary infection. Her most recent CD4 cell count was over 1.5x 109/L, and the results of her in vitro lymphocyte proliferation tests became progressively normal, showing an association between the clinical and immunologic improvements. In most cases of HIV-infected children, there is a correlation between the severity of the symptoms and the impairment of the immune system or the intensity of the viral load. However, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?